Persistence of antigen presenting cell-mediated HIV trans infection during cART

Persistence of antigen presenting cell-mediated HIV trans infection during cART

Bibliographic Details
Main Authors:	G. Rappocciolo, D.C. Delucia, N. Sluis-Cremer, C.R. Rinaldo
Format:	Article
Language:	English
Published:	Elsevier 2017-12-01
Series:	Journal of Virus Eradication
Online Access:	http://www.sciencedirect.com/science/article/pii/S2055664020306373

Similar Items

B cells mediate R5-Tropic HIV infection of CCR5neg naive CD4 T cells
by: A. Gerberick, et al.
Published: (2019-12-01)

Dendritic cell induced “kick” of latent HIV-1 in vitro during cART
by: R.B. Mailliard, et al.
Published: (2015-12-01)

HIV-1 Trans Infection of CD4+ T Cells by Professional Antigen Presenting Cells
by: Charles R. Rinaldo
Published: (2013-01-01)

Type 1-programmed dendritic cells drive antigen-specific latency reversal and immune elimination of persistent HIV-1Research in context
by: Jan Kristoff, et al.
Published: (2019-05-01)

High HIV viral burden persists in CXCR3+TFH despite very early cART initiation
by: O. Baiyegunhi, et al.
Published: (2019-07-01)

Persistence of anal squamous intraepithelial lesions and anal HPV infection in HIV-infected patientsdespite immune restoration under cART
by: Tartour E, et al.
Published: (2010-10-01)

HIV and cART-Associated Dyslipidemia Among HIV-Infected Children
by: Birkneh Tilahun Tadesse, et al.
Published: (2019-03-01)

Professional antigen presenting cells in human herpesvirus 8 infection
by: Emilee R Knowlton, et al.
Published: (2013-01-01)

Changes in RANKL during the first two years after cART initiation in HIV-infected cART naïve adults
by: Inger Hee Mathiesen, et al.
Published: (2017-04-01)

28 Dendritic cells programmed by inflammatory mediators can effectively induce both the immunologic ‘kick’ and ‘kill’ of latent HIV-1
by: J. Kristoff, et al.
Published: (2016-07-01)

Neurological Response to cART vs. cART plus Integrase Inhibitor and CCR5 Antagonist Initiated during Acute HIV.
by: Victor G Valcour, et al.
Published: (2015-01-01)

Consequences of persistent antigen presentation following administration of HIV-1-derived lentiviral vectors
by: Arce Vargus, F.
Published: (2010)

Symptomatic HIV CNS viral escape among patients on effective cART
by: Abi Manesh, et al.
Published: (2019-07-01)

Review The Emerging Profile of Cross-Resistance among the Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors
by: Nicolas Sluis-Cremer
Published: (2014-07-01)

HIV-Associated Hodgkin's Lymphoma: Prognosis and Therapy in the Era of cART
by: Caron A. Jacobson, et al.
Published: (2012-01-01)

Monocytes as Regulators of Inflammation and HIV-Related Comorbidities during cART
by: Joshua J. Anzinger, et al.
Published: (2014-01-01)

Virologic and immunologic response to cART by HIV-1 subtype in the CASCADE collaboration.
by: Giota Touloumi, et al.
Published: (2013-01-01)

Delay in cART initiation results in persistent immune dysregulation and poor recovery of T-cell phenotype despite a decade of successful HIV suppression.
by: Patricia Ndumbi, et al.
Published: (2014-01-01)

Development of Stable Chimeric IL-15 for Trans-Presentation by the Antigen Presenting Cells
by: Manoj Patidar, et al.
Published: (2021-04-01)

41 Vitamin D level in cART treated patients is critical for HIV reservoir size
by: A. Chéret, et al.
Published: (2016-07-01)

Monitoring HIV DNA and cellular activation markers in HIV-infected humanized mice under cART
by: Mary-Aude Rochat, et al.
Published: (2018-12-01)

HIV Status Disclosure Among People Living with HIV in the Era of Combination Antiretroviral Therapy (cART)
by: Deepak Madi, et al.
Published: (2015-08-01)

HIV-1 selectively exploits cross-reactive CTL “help” to promote dysfunctional programming of pro-inflammatory dendritic cells
by: Mailliard RB, et al.
Published: (2012-09-01)

49 Using ddPCR to assess persistence of HIV DNA reservoirs in perinatally infected infants treated with cART before or after 12 months of age
by: P. Soni, et al.
Published: (2016-07-01)

Impact of early cART on HIV blood and semen compartments at the time of primary infection.
by: Antoine Chéret, et al.
Published: (2017-01-01)

HIV DNA reservoir increases risk for cognitive disorders in cART-naïve patients.
by: Victor G Valcour, et al.
Published: (2013-01-01)

MR spectroscopy in HIV associated neurocognitive disorder in the era of cART: a review
by: Joga Chaganti, et al.
Published: (2021-10-01)

Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART)
by: Jenny Bischoff, et al.
Published: (2021-10-01)

HIV-associated cognitive performance and psychomotor impairment in a Thai cohort on long-term cART
by: Tanya C. Do, et al.
Published: (2018-01-01)

Subunit-specific mutational analysis of residue N348 in HIV-1 reverse transcriptase
by: Radzio Jessica, et al.
Published: (2011-08-01)

HIV-1 persistence during ART
by: Ruggiero, Alessandra
Published: (2016)

The Impact of HCV Infection Duration on HIV Disease Progression and Response to cART amongst HIV Seroconverters in the UK.
by: Jamie Inshaw, et al.
Published: (2015-01-01)

NNRTIs reduce HIV-1 production from latently infected resting CD4+ T cells
by: J. Zerbato, et al.
Published: (2015-12-01)

Early skewed differentiation and PD-1 expression in CD4+ cells relate to immune dysfunction and viral persistence in individuals living with HIV 1 year post-cART initiation
by: J. Salido, et al.
Published: (2019-07-01)

Antigen Presenting Cells Contribute to Persistent Immune Activation Despite Antiretroviral Therapy Initiation During Hyperacute HIV-1 Infection
by: Kewreshini K. Naidoo, et al.
Published: (2021-09-01)

Correction: HIV DNA Reservoir Increases Risk for Cognitive Disorders in cART-Naïve Patients
by: Victor G. Valcour, et al.
Published: (2014-01-01)

T-cell phenotypes, apoptosis and inflammation in HIV+ patients on virologically effective cART with early atherosclerosis.
by: Esther Merlini, et al.
Published: (2012-01-01)

Correction: HIV DNA Reservoir Increases Risk for Cognitive Disorders in cART-Naïve Patients.
by: Victor G. Valcour, et al.
Published: (2014-01-01)

The cost-effectiveness of early access to HIV services and starting cART in the UK 1996-2008.
by: Eduard J Beck, et al.
Published: (2011-01-01)

HIV conserved region vaccine in early cART-treated subjects (BCN01): impact on immunogenicity and the latent reservoir
by: S. Morón-López, et al.
Published: (2015-12-01)

Cannot write session to /tmp/vufind_sessions/sess_7e94eahhf5aklsnh3iu0ukiojh